Patent Application Titled "Methods Of Treating B-Cell Proliferative Disorder" Published Online (USPTO 20240131030).

The patent application titled "Methods Of Treating B-Cell Proliferative Disorder" discusses a method of treating B-cell proliferative disorders, such as chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), using a drug called zanubrutinib. The inventors propose administering zanubrutinib along with a moderate CYP3A inducer to extend progression-free survival and reduce side effects. The application includes specific dosing recommendations and eligibility criteria for patients. It also addresses the assessment and treatment of tumor lysis syndrome (TLS) during treatment. For more detailed information and claims, readers can refer to the patent application. [Extracted from the article]